BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 15, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 1/12 cls
Genentech (DNA) Rodman Michael King Price target Market outperform 4% $86.83
Stifel, Nicolaus Edward Nash Price target Buy
King raised his target to $96 from $87 after DNA posted 4Q06 non-GAAP diluted EPS of $0.61, beating by $0.05...

Read the full 382 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >